Skip to main content
. 2021 Jul 12;12:701501. doi: 10.3389/fimmu.2021.701501

Table 1.

Summary of the redesign of the complete S glycoprotein used in vaccines against SARS-CoV-2.

Developers Vaccine Vaccine platform Administration (# doses) Unfolded S protein design
Vaxart VXA-CoV2-1 nrVV Oral (2) graphic file with name fimmu-12-701501-g006.jpg
Arcturus Therapeutics LUNAR-COV-19/ARCT-021 RNA ND
AstraZeneca + University of Oxford Chadox1/AZD1222 nrVV IM (2) graphic file with name fimmu-12-701501-g007.jpg
CanSino Biological Inc. + Beijing Institute of Biotechnology Ad5-nCoV nrVV IM (1)
Genexine Consortium GX-19 DNA IM (2) graphic file with name fimmu-12-701501-g008.jpg
ReiThera + Leukocare + Univercells GRAd-COV2 nrVV IM (1) graphic file with name fimmu-12-701501-g009.jpg
University of Munich (Ludwig-Maximilians) MVA-SARS-2-S nrVV IM (2) graphic file with name fimmu-12-701501-g010.jpg
Pfizer-Biontech BNT162b2 nrVV IM(2)
Moderna mRNA-1273 RNA IM(2) graphic file with name fimmu-12-701501-g011.jpg
Inovio Pharmaceuticals + International Vaccine Institute + Advaccine (Suzhou) Biopharmaceutical Co., Ltd INO-4800 DNA ID (2) graphic file with name fimmu-12-701501-g012.jpg
Janssen Pharmaceutical Ad26.COV2.S nrVV IM (2) graphic file with name fimmu-12-701501-g013.jpg
Novavax NVX-CoV2373 PS IM (2)
Clover Biopharmaceuticals Inc. + GSK + Dynavax SCB-2019 PS IM (2) graphic file with name fimmu-12-701501-g014.jpg
CSL Ltd. + Seqirus + University of Queensland Sclamp PS IM (2) graphic file with name fimmu-12-701501-g015.jpg
Medicago Inc. Plant-based VLP / Co-VLP VLP IM (2) graphic file with name fimmu-12-701501-g016.jpg
The University of Texas HexaPro PS ND graphic file with name fimmu-12-701501-g017.jpg
Stanford University SΔC-Fer VLP ND graphic file with name fimmu-12-701501-g018.jpg

Vaccine platform acronym: nrW, non replicating viral vector; RNA, ribonucleic acid; DNA, desoxyribonucleic acid; PS, protein subunit; VLP, virus like particle. Route of administration. Oral, ND, no data; IM, intramuscular; ID, intradermal.